Literature DB >> 10747284

Outcome of meningitis caused by Streptococcus pneumoniae and Haemophilus influenzae type b in children in The Gambia.

T Goetghebuer1, T E West, V Wermenbol, A L Cadbury, P Milligan, N Lloyd-Evans, R A Adegbola, E K Mulholland, B M Greenwood, M W Weber.   

Abstract

In developing countries, endemic childhood meningitis is a severe disease caused most commonly by Streptococcus pneumoniae or Haemophilus influenzae type b (Hib). Although many studies have shown that fatality rates associated with meningitis caused by these organisms are high in developing countries, little is known about the long-term outcome of survivors. The purpose of this study was to assess the importance of disabilities following pneumococcal and Hib meningitis in The Gambia. 257 children aged 0-12 years hospitalized between 1990 and 1995 with culture-proven S. pneumoniae (n = 134) or Hib (n = 123) meningitis were included retrospectively in the study. 48% of children with pneumococcal meningitis and 27% of children with Hib meningitis died whilst in hospital. Of the 160 survivors, 89 (55%) were followed up between September 1996 and October 1997. Of the children with pneumococcal meningitis that were traced, 58% had clinical sequelae; half of them had major disabilities preventing normal adaptation to social life. 38% of survivors of Hib meningitis had clinical sequelae, a quarter of whom had major disabilities. Major handicaps found were hearing loss, mental retardation, motor abnormalities and seizures. These data show that despite treatment with effective antibiotics, pneumococcal and Hib meningitis kill many Gambian children and leave many survivors with severe sequelae. Hib vaccination is now given routinely in The Gambia; an effective pneumococcal vaccine is needed.

Entities:  

Mesh:

Year:  2000        PMID: 10747284     DOI: 10.1046/j.1365-3156.2000.00535.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  24 in total

1.  Laboratory-based surveillance for patients with acute meningitis in Sudan, 2004-2005.

Authors:  S Afifi; M S Karsany; M Wasfy; G Pimentel; A Marfin; R Hajjeh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-11-12       Impact factor: 3.267

Review 2.  Valuing vaccination.

Authors:  Till Bärnighausen; David E Bloom; Elizabeth T Cafiero-Fonseca; Jennifer Carroll O'Brien
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

3.  Clinical data and factors associated with poor outcome in pneumococcal meningitis.

Authors:  Juan Casado-Flores; Javier Aristegui; Carlos Rodrigo de Liria; Jose María Martinón; Cristina Fernández
Journal:  Eur J Pediatr       Date:  2005-12-07       Impact factor: 3.183

4.  Economic evaluation of pneumococcal conjugate vaccination in The Gambia.

Authors:  Sun-Young Kim; Gene Lee; Sue J Goldie
Journal:  BMC Infect Dis       Date:  2010-09-03       Impact factor: 3.090

5.  Elevated cytokines in pneumococcal meningitis: Chicken or egg?

Authors:  Enitan D Carrol; Paul Baines
Journal:  Crit Care Med       Date:  2005-05       Impact factor: 7.598

Review 6.  Long Term Impact of Conjugate Vaccines on Haemophilus influenzae Meningitis: Narrative Review.

Authors:  Mary Paulina Elizabeth Slack
Journal:  Microorganisms       Date:  2021-04-21

7.  Pattern of paediatric neurological disorders in port harcourt, Nigeria.

Authors:  A I Frank-Briggs; E A D Alikor
Journal:  Int J Biomed Sci       Date:  2011-06

8.  Significant sequelae after bacterial meningitis in Niger: a cohort study.

Authors:  Jean-François Jusot; Zilahatou Tohon; Abdoul Aziz Yazi; Jean-Marc Collard
Journal:  BMC Infect Dis       Date:  2013-05-21       Impact factor: 3.090

9.  Predictors of long term neurological outcome in bacterial meningitis.

Authors:  Pratibha Singhi; Arun Bansal; P Geeta; Sunit Singhi
Journal:  Indian J Pediatr       Date:  2007-04       Impact factor: 5.319

10.  Pneumococcal antibody concentrations and carriage of pneumococci more than 3 years after infant immunization with a pneumococcal conjugate vaccine.

Authors:  Adebayo K Akinsola; Martin O C Ota; Godwin C Enwere; Brown J Okoko; Syed M A Zaman; Mark Saaka; Ekpedeme D Nsekpong; Aderonke A Odutola; Brian M Greenwood; Felicity T Cutts; Richard A Adegbola
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.